首页 > 最新文献

International journal of clinical pharmacology and therapeutics最新文献

英文 中文
Evidence for a loss of analgesia when hydromorphone is administered in combination with hange-shashin-to: Enterohepatic circulation and β-glucuronidase inhibition.
IF 0.9 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2025-04-01 DOI: 10.5414/CP204702
Masakazu Ozaki, Hiroshi Yamagata, Hiroto Matsui, Naoto Okada, Mishiya Matsumoto, Hiroaki Nagano, Takashi Kitahara
{"title":"Evidence for a loss of analgesia when hydromorphone is administered in combination with hange-shashin-to: Enterohepatic circulation and β-glucuronidase inhibition.","authors":"Masakazu Ozaki, Hiroshi Yamagata, Hiroto Matsui, Naoto Okada, Mishiya Matsumoto, Hiroaki Nagano, Takashi Kitahara","doi":"10.5414/CP204702","DOIUrl":"10.5414/CP204702","url":null,"abstract":"","PeriodicalId":13963,"journal":{"name":"International journal of clinical pharmacology and therapeutics","volume":" ","pages":"174-176"},"PeriodicalIF":0.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Niraparib-related severe refractory thrombocytopenia in ovarian cancer patients receiving paclitaxel/carboplatin chemotherapy: A report on three cases.
IF 0.9 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2025-04-01 DOI: 10.5414/CP204724
Mingtao Chen, Lin Zhou, Huijuan Yang, Mengmeng Wang

A characteristic toxicity of niraparib is a decrease in blood platelets (PLT), with an incidence of ~ 34% for grades 3 - 4 conditions. However, exceedingly severe cases have been reported infrequently. This paper describes three patients with acute and refractory severe PLT deficiency due to niraparib administration. The symptom characteristics, treatment course, and outcomes have also been analyzed, and the potential for the involvement of immune-related factors is considered. Therefore, it is recommended to comprehensively assess bone marrow hematopoietic function and high-risk variables before administering niraparib, intensify self-management and monitoring of patients, track changes in indicators, and intervene promptly. Additionally, if standard PLT-elevating therapies are ineffective, early full-dose administration of thrombopoietin receptor agonists, preferably avatrombopag, may be beneficial for reversing PLT loss of control.

{"title":"Niraparib-related severe refractory thrombocytopenia in ovarian cancer patients receiving paclitaxel/carboplatin chemotherapy: A report on three cases.","authors":"Mingtao Chen, Lin Zhou, Huijuan Yang, Mengmeng Wang","doi":"10.5414/CP204724","DOIUrl":"10.5414/CP204724","url":null,"abstract":"<p><p>A characteristic toxicity of niraparib is a decrease in blood platelets (PLT), with an incidence of ~ 34% for grades 3 - 4 conditions. However, exceedingly severe cases have been reported infrequently. This paper describes three patients with acute and refractory severe PLT deficiency due to niraparib administration. The symptom characteristics, treatment course, and outcomes have also been analyzed, and the potential for the involvement of immune-related factors is considered. Therefore, it is recommended to comprehensively assess bone marrow hematopoietic function and high-risk variables before administering niraparib, intensify self-management and monitoring of patients, track changes in indicators, and intervene promptly. Additionally, if standard PLT-elevating therapies are ineffective, early full-dose administration of thrombopoietin receptor agonists, preferably avatrombopag, may be beneficial for reversing PLT loss of control.</p>","PeriodicalId":13963,"journal":{"name":"International journal of clinical pharmacology and therapeutics","volume":" ","pages":"169-173"},"PeriodicalIF":0.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143382260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiovascular safety profile of JAK inhibitors and ethnic factors in Asians: A signal detection study using the Global ICSR (WHO-UMC VigBase) database.
IF 0.9 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2025-04-01 DOI: 10.5414/CP204580
Woongshik Nam, Ji-Hwan Bae, Jeongin Oh, Ju-Young Shin, Hoon Kim

Objective: This study aimed to detect cardiovascular disease-related signals using Global Individual Case Safety Report data on JAK inhibitors.

Materials and methods: A signal detection study was conducted using the WHO-UMC VigiBase.

Results: This study identified four cardiovascular adverse event signals associated with JAK inhibitors in Asian populations, including pulmonary embolism, deep vein thrombosis, thrombosis, and cerebrovascular accidents.

Conclusion: Analysis of Asian populations revealed a higher risk of thromboembolic events associated with JAK inhibitors than with TNF inhibitors. However, unlike in the Western populations, no myocardial infarction signal was detected in the Asian populations.

{"title":"Cardiovascular safety profile of JAK inhibitors and ethnic factors in Asians: A signal detection study using the Global ICSR (WHO-UMC VigBase) database.","authors":"Woongshik Nam, Ji-Hwan Bae, Jeongin Oh, Ju-Young Shin, Hoon Kim","doi":"10.5414/CP204580","DOIUrl":"10.5414/CP204580","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to detect cardiovascular disease-related signals using Global Individual Case Safety Report data on JAK inhibitors.</p><p><strong>Materials and methods: </strong>A signal detection study was conducted using the WHO-UMC VigiBase.</p><p><strong>Results: </strong>This study identified four cardiovascular adverse event signals associated with JAK inhibitors in Asian populations, including pulmonary embolism, deep vein thrombosis, thrombosis, and cerebrovascular accidents.</p><p><strong>Conclusion: </strong>Analysis of Asian populations revealed a higher risk of thromboembolic events associated with JAK inhibitors than with TNF inhibitors. However, unlike in the Western populations, no myocardial infarction signal was detected in the Asian populations.</p>","PeriodicalId":13963,"journal":{"name":"International journal of clinical pharmacology and therapeutics","volume":" ","pages":"160-163"},"PeriodicalIF":0.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Severe genital cutaneous toxicity with sunitinib. 苏尼替尼严重的生殖器皮肤毒性。
IF 0.9 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2025-04-01 DOI: 10.5414/CP204697
María Rodríguez Jorge, Loreto Domínguez Senín, Stephanie Saide Cobelas Cartagena, María Sánchez Esperilla, Juan Bayo Calero

Introduction: Sunitinib is an oral drug approved for the treatment of metastatic renal cell carcinoma. Serious cutaneous adverse reactions to sunitinib are rare, and when they occur, discontinuation of the treatment may be needed.

Case report: A 70-year-old male patient was diagnosed with stage IV clear cell renal carcinoma and received treatment with sunitinib. After a second cycle with a 25% dose reduction, the patient was admitted with a diagnosis of grade 3 genital erythema. After ruling out other common causes, sunitinib was considered the cause of genital erythema and was stopped. Treatment with corticosteroids, topical applications, and morphine was started, with resolution after 18 days of evolution.

Discussion: There are only a few published reports that describe erythema and scaling of the genital skin. As in those few cases, for our patient, the first clinical signs appeared on day 28 of sunitinib treatment, and the lesions disappeared after 2 weeks without the use of the drug. Erythema and scaling reappeared when the drug was reintroduced, with greater severity than what was described in some of the other cases, which even included cases for which the lesions did not reappear.

Conclusion: Rare instances of severe and limiting skin toxicity may necessitate treatment suspension and compromise survival, as observed in our case. It is crucial to recognize these skin toxicities and understand their appropriate management strategies to initiate treatment as early as possible, thereby avoiding hospitalizations and enabling the resumption of sunitinib therapy.

舒尼替尼是一种被批准用于治疗转移性肾细胞癌的口服药物。舒尼替尼严重的皮肤不良反应是罕见的,当它们发生时,可能需要停止治疗。病例报告:一位70岁男性患者被诊断为IV期透明细胞肾癌并接受舒尼替尼治疗。在第二个周期减少25%的剂量后,患者被诊断为3级生殖器红斑。在排除其他常见原因后,舒尼替尼被认为是生殖器红斑的原因,并被停止使用。开始使用皮质类固醇、局部应用和吗啡治疗,18天后病情好转。讨论:只有少数已发表的报告描述了生殖器皮肤的红斑和鳞屑。与少数病例一样,我们的患者在舒尼替尼治疗的第28天出现了第一个临床症状,2周后病变消失。当药物重新引入时,红斑和鳞屑再次出现,比其他一些病例所描述的更严重,甚至包括病变没有再次出现的病例。结论:正如本病例所观察到的,罕见的严重和有限的皮肤毒性可能需要暂停治疗并危及生存。至关重要的是要认识到这些皮肤毒性,并了解其适当的管理策略,以便尽早开始治疗,从而避免住院并恢复舒尼替尼治疗。
{"title":"Severe genital cutaneous toxicity with sunitinib.","authors":"María Rodríguez Jorge, Loreto Domínguez Senín, Stephanie Saide Cobelas Cartagena, María Sánchez Esperilla, Juan Bayo Calero","doi":"10.5414/CP204697","DOIUrl":"10.5414/CP204697","url":null,"abstract":"<p><strong>Introduction: </strong>Sunitinib is an oral drug approved for the treatment of metastatic renal cell carcinoma. Serious cutaneous adverse reactions to sunitinib are rare, and when they occur, discontinuation of the treatment may be needed.</p><p><strong>Case report: </strong>A 70-year-old male patient was diagnosed with stage IV clear cell renal carcinoma and received treatment with sunitinib. After a second cycle with a 25% dose reduction, the patient was admitted with a diagnosis of grade 3 genital erythema. After ruling out other common causes, sunitinib was considered the cause of genital erythema and was stopped. Treatment with corticosteroids, topical applications, and morphine was started, with resolution after 18 days of evolution.</p><p><strong>Discussion: </strong>There are only a few published reports that describe erythema and scaling of the genital skin. As in those few cases, for our patient, the first clinical signs appeared on day 28 of sunitinib treatment, and the lesions disappeared after 2 weeks without the use of the drug. Erythema and scaling reappeared when the drug was reintroduced, with greater severity than what was described in some of the other cases, which even included cases for which the lesions did not reappear.</p><p><strong>Conclusion: </strong>Rare instances of severe and limiting skin toxicity may necessitate treatment suspension and compromise survival, as observed in our case. It is crucial to recognize these skin toxicities and understand their appropriate management strategies to initiate treatment as early as possible, thereby avoiding hospitalizations and enabling the resumption of sunitinib therapy.</p>","PeriodicalId":13963,"journal":{"name":"International journal of clinical pharmacology and therapeutics","volume":" ","pages":"164-168"},"PeriodicalIF":0.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142948509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Renoprotective effects of dulaglutide, a GLP-1 agonist, involving regulation of epithelial-mesenchymal transition in patients with type 2 diabetes and diabetic kidney disease. GLP-1激动剂dulaglutide的肾保护作用,涉及调节2型糖尿病和糖尿病肾病患者的上皮-间质转化。
IF 0.9 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2025-04-01 DOI: 10.5414/CP204632
Daoli Jiang, Fandong Meng, Xiaohua Chou, Jiaxin Shen, Miaoyan Liu

Aims: To assess the renoprotective effects of dulaglutide and identify mechanisms of action in patients with type 2 diabetes and diabetic kidney disease (DKD).

Materials and methods: Outpatients/ambulant patients at the Department of Endocrinology, Affiliated Hospital of Xuzhou Medical University between October 2021 and July 2023, with type 2 diabetes and DKD, a urinary albumin-to-creatinine ratio (UACR) ≥ 3 mg/mmol and who were receiving hypoglycemic agents were prescribed dulaglutide at a dose rate of 0.75 - 1.5 mg once weekly (intervention group; n = 70). Patients receiving hypoglycemic agents other than glucagon-like peptide-1 (GLP-1) receptor agonists and who were not prescribed dulaglutide constituted the control group (n = 65). Observations/outcomes: The primary outcome was a change in the UACR and biomarkers of epithelial-mesenchymal transition (EMT) determined after 12 months of intervention treatment. Adverse events (estimates of tolerability and safety) were recorded during treatment and a follow-up period of 12 months.

Results: UACR changes in the intervention group compared to the control group were significantly lower (p < 0.01 at 6 months and p < 0.05 at 12 months). The frequency of gastrointestinal adverse events in the two groups were not significantly different, and there were no significant increases in the number of hypoglycemic events. Dulaglutide significantly increased the epithelial marker E-cadherin and inhibited the mesenchymal marker periostin.

Conclusion: It is concluded that dulaglutide causes significant reductions in urinary albumin and modulates EMT-related proteins thereby ameliorating the decline in kidney function in patients with type 2 diabetes and DKD.

目的:评估杜拉鲁肽对2型糖尿病和糖尿病肾病(DKD)患者的肾保护作用,并确定其作用机制。材料与方法:2021年10月至2023年7月在徐州医科大学附属医院内分泌科门诊/门诊就诊的2型糖尿病合并DKD患者,尿白蛋白/肌酐比值(UACR)≥3mg /mmol,正在接受降糖药治疗的患者均给予度拉鲁肽,剂量率为0.75 ~ 1.5 mg,每周1次(干预组;N = 70)。对照组为接受胰高血糖素样肽-1 (GLP-1)受体激动剂以外降糖药物治疗且未使用杜拉鲁肽的患者(n = 65)。观察/结果:主要结果是干预治疗12个月后UACR和上皮-间质转化(EMT)生物标志物的变化。在治疗期间和12个月的随访期间记录不良事件(耐受性和安全性的估计)。结果:干预组UACR变化明显低于对照组(6个月时p < 0.01, 12个月时p < 0.05)。两组患者胃肠道不良事件发生频率无显著差异,低血糖事件发生次数无显著增加。杜拉鲁肽显著提高上皮标志物E-cadherin,抑制间质标志物periostin。结论:杜拉鲁肽可显著降低尿白蛋白并调节emt相关蛋白,从而改善2型糖尿病合并DKD患者的肾功能下降。
{"title":"Renoprotective effects of dulaglutide, a GLP-1 agonist, involving regulation of epithelial-mesenchymal transition in patients with type 2 diabetes and diabetic kidney disease.","authors":"Daoli Jiang, Fandong Meng, Xiaohua Chou, Jiaxin Shen, Miaoyan Liu","doi":"10.5414/CP204632","DOIUrl":"10.5414/CP204632","url":null,"abstract":"<p><strong>Aims: </strong>To assess the renoprotective effects of dulaglutide and identify mechanisms of action in patients with type 2 diabetes and diabetic kidney disease (DKD).</p><p><strong>Materials and methods: </strong>Outpatients/ambulant patients at the Department of Endocrinology, Affiliated Hospital of Xuzhou Medical University between October 2021 and July 2023, with type 2 diabetes and DKD, a urinary albumin-to-creatinine ratio (UACR) ≥ 3 mg/mmol and who were receiving hypoglycemic agents were prescribed dulaglutide at a dose rate of 0.75 - 1.5 mg once weekly (intervention group; n = 70). Patients receiving hypoglycemic agents other than glucagon-like peptide-1 (GLP-1) receptor agonists and who were not prescribed dulaglutide constituted the control group (n = 65). Observations/outcomes: The primary outcome was a change in the UACR and biomarkers of epithelial-mesenchymal transition (EMT) determined after 12 months of intervention treatment. Adverse events (estimates of tolerability and safety) were recorded during treatment and a follow-up period of 12 months.</p><p><strong>Results: </strong>UACR changes in the intervention group compared to the control group were significantly lower (p < 0.01 at 6 months and p < 0.05 at 12 months). The frequency of gastrointestinal adverse events in the two groups were not significantly different, and there were no significant increases in the number of hypoglycemic events. Dulaglutide significantly increased the epithelial marker E-cadherin and inhibited the mesenchymal marker periostin.</p><p><strong>Conclusion: </strong>It is concluded that dulaglutide causes significant reductions in urinary albumin and modulates EMT-related proteins thereby ameliorating the decline in kidney function in patients with type 2 diabetes and DKD.</p>","PeriodicalId":13963,"journal":{"name":"International journal of clinical pharmacology and therapeutics","volume":" ","pages":"141-153"},"PeriodicalIF":0.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142948506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bisphosphonates in combination with alendronate sodium increase bone mineral density and modulate IL-6, TNF-α, and IGF-1 in patients with osteoporosis.
IF 0.9 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2025-04-01 DOI: 10.5414/CP204706
Xuechun Gu, Liyuan Zhang, Xiangyi Chen, Lingyan Kong

Objective: To assess the effects of bisphosphonates (zoledronic acid injection) plus alendronate sodium on bone mineral density (BMD) and levels of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and insulin-like growth factor I (IGF-I) in patients with osteoporosis.

Materials and methods: A total of 94 patients recruited from osteoporosis patients hospitalized in the period October 2021 to December 2022 were assigned to either a control group or an observation group using a random number table. The control group was treated with alendronate sodium alone, whereas the observation group received zoledronic acid injection in combination with alendronate sodium administered orally.

Results: Pre-treatment values for BMD, serum levels of IL-6, TNF-α, and IGF-I did not differ between the two groups (p > 0.05). However, post-treatment BMD measured at the femoral neck, in lumbar vertebrae, and Ward's triangle were increased, as was serum IGF-I level (p < 0.05). In contrast, in comparison with the control group, reductions were observed in serum IL-6 and TNF-α (p < 0.05). The incidence of adverse reactions such as nausea and vomiting, diarrhea, musculoskeletal pain, and hypocalcemia was significantly lower in the observation group (p < 0.05).

Conclusion: Zoledronic acid injection in combination with alendronate sodium increases the expression of IL-6, TNF-α, and IGF-I, suppresses bone resorption and promotes bone recovery in patients with osteoporosis.

研究目的评估双膦酸盐(唑来膦酸注射液)加阿仑膦酸钠对骨质疏松症患者骨矿物质密度(BMD)以及白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)和胰岛素样生长因子I(IGF-I)水平的影响:从 2021 年 10 月至 2022 年 12 月期间住院的骨质疏松症患者中招募 94 名患者,采用随机数字表法将其分配到对照组或观察组。对照组单独接受阿仑膦酸钠治疗,而观察组则接受唑来膦酸注射液与阿仑膦酸钠联合口服治疗:结果:两组治疗前的 BMD 值、血清 IL-6、TNF-α 和 IGF-I 水平没有差异(P > 0.05)。然而,治疗后股骨颈、腰椎和 Ward 三角区的 BMD 测量值和血清 IGF-I 水平均有所增加(P唑来膦酸注射液联合阿仑膦酸钠可增加 IL-6、TNF-α 和 IGF-I 的表达,抑制骨吸收,促进骨质疏松症患者的骨恢复。
{"title":"Bisphosphonates in combination with alendronate sodium increase bone mineral density and modulate IL-6, TNF-α, and IGF-1 in patients with osteoporosis.","authors":"Xuechun Gu, Liyuan Zhang, Xiangyi Chen, Lingyan Kong","doi":"10.5414/CP204706","DOIUrl":"10.5414/CP204706","url":null,"abstract":"<p><strong>Objective: </strong>To assess the effects of bisphosphonates (zoledronic acid injection) plus alendronate sodium on bone mineral density (BMD) and levels of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and insulin-like growth factor I (IGF-I) in patients with osteoporosis.</p><p><strong>Materials and methods: </strong>A total of 94 patients recruited from osteoporosis patients hospitalized in the period October 2021 to December 2022 were assigned to either a control group or an observation group using a random number table. The control group was treated with alendronate sodium alone, whereas the observation group received zoledronic acid injection in combination with alendronate sodium administered orally.</p><p><strong>Results: </strong>Pre-treatment values for BMD, serum levels of IL-6, TNF-α, and IGF-I did not differ between the two groups (p > 0.05). However, post-treatment BMD measured at the femoral neck, in lumbar vertebrae, and Ward's triangle were increased, as was serum IGF-I level (p < 0.05). In contrast, in comparison with the control group, reductions were observed in serum IL-6 and TNF-α (p < 0.05). The incidence of adverse reactions such as nausea and vomiting, diarrhea, musculoskeletal pain, and hypocalcemia was significantly lower in the observation group (p < 0.05).</p><p><strong>Conclusion: </strong>Zoledronic acid injection in combination with alendronate sodium increases the expression of IL-6, TNF-α, and IGF-I, suppresses bone resorption and promotes bone recovery in patients with osteoporosis.</p>","PeriodicalId":13963,"journal":{"name":"International journal of clinical pharmacology and therapeutics","volume":" ","pages":"154-159"},"PeriodicalIF":0.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bioequivalence study of two formulations of teriflunomide tablets in a healthy Chinese population under fasting and fed conditions.
IF 0.9 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2025-03-31 DOI: 10.5414/CP204734
Xiaomin Sun, Ronghua Zhu, Jinmiao Lu, Jingjing Li, Juping Ding, Qiang Yu, Xiao Fan, Xiding Yan, Qiangyong Yan, Lingfeng Yang, Pingfei Fang

Aims: The aims of this study were to evaluate and compare the pharmacokinetic profiles and establish bioequivalence of test and reference teriflunomide tablets (Aubagio) in healthy Chinese male subjects under fasting and fed conditions.

Materials and methods: Subjects were randomly assigned to either the fasting or the fed group and also to one of the two treatment sequences (test-reference or reference-test), according to which they received a single 14-mg dose of the test or reference teriflunomide tablet in the study periods. During each period, blood samples were collected at pre-dose and at intervals up to 72 hours after dosing. After 72 hours post dose, an accelerated elimination procedure using cholestyramine 4 g t.i.d. PO was done. Plasma concentrations of teriflunomide were determined by liquid chromatography-tandem mass spectrometry. The safety of both tablets was monitored throughout the study.

Results: 48 subjects were enrolled, and all completed the study, with 24 participants each in the fasting and fed groups. In both groups, the 90% confidence intervals for AUC0-72h and Cmax were within the acceptable bioequivalence range (80 - 125%). There were no significant differences in adverse event (AE) reporting between the subjects receiving test or reference tablet. No serious AEs occurred during the study period.

Conclusion: The test teriflunomide tablet was pharmacokinetic bioequivalent to the reference teriflunomide tablet (Aubagio) in healthy Chinese male subjects under both fasting and fed conditions. Both formulations were well tolerated by all study participants.

{"title":"Bioequivalence study of two formulations of teriflunomide tablets in a healthy Chinese population under fasting and fed conditions.","authors":"Xiaomin Sun, Ronghua Zhu, Jinmiao Lu, Jingjing Li, Juping Ding, Qiang Yu, Xiao Fan, Xiding Yan, Qiangyong Yan, Lingfeng Yang, Pingfei Fang","doi":"10.5414/CP204734","DOIUrl":"https://doi.org/10.5414/CP204734","url":null,"abstract":"<p><strong>Aims: </strong>The aims of this study were to evaluate and compare the pharmacokinetic profiles and establish bioequivalence of test and reference teriflunomide tablets (Aubagio) in healthy Chinese male subjects under fasting and fed conditions.</p><p><strong>Materials and methods: </strong>Subjects were randomly assigned to either the fasting or the fed group and also to one of the two treatment sequences (test-reference or reference-test), according to which they received a single 14-mg dose of the test or reference teriflunomide tablet in the study periods. During each period, blood samples were collected at pre-dose and at intervals up to 72 hours after dosing. After 72 hours post dose, an accelerated elimination procedure using cholestyramine 4 g t.i.d. PO was done. Plasma concentrations of teriflunomide were determined by liquid chromatography-tandem mass spectrometry. The safety of both tablets was monitored throughout the study.</p><p><strong>Results: </strong>48 subjects were enrolled, and all completed the study, with 24 participants each in the fasting and fed groups. In both groups, the 90% confidence intervals for AUC<sub>0-72h</sub> and C<sub>max</sub> were within the acceptable bioequivalence range (80 - 125%). There were no significant differences in adverse event (AE) reporting between the subjects receiving test or reference tablet. No serious AEs occurred during the study period.</p><p><strong>Conclusion: </strong>The test teriflunomide tablet was pharmacokinetic bioequivalent to the reference teriflunomide tablet (Aubagio) in healthy Chinese male subjects under both fasting and fed conditions. Both formulations were well tolerated by all study participants.</p>","PeriodicalId":13963,"journal":{"name":"International journal of clinical pharmacology and therapeutics","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Taken from the Radio Times newspaper (U.K.) December 18, 1931.
IF 0.9 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2025-03-28 DOI: 10.5414/CPP63177
Barrington G Woodcock-Kloberdanz
{"title":"Taken from the Radio Times newspaper (U.K.) December 18, 1931.","authors":"Barrington G Woodcock-Kloberdanz","doi":"10.5414/CPP63177","DOIUrl":"10.5414/CPP63177","url":null,"abstract":"","PeriodicalId":13963,"journal":{"name":"International journal of clinical pharmacology and therapeutics","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143730010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical effects of atomizing inhalation of antibiotics on germ clearance rate and adverse reactions in respiratory infectious diseases: A meta-analysis.
IF 0.9 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2025-03-21 DOI: 10.5414/CP204722
Chunyu Li, Jia Chen, Lujia Chen

Objective: To assess the effects of atomizing inhalation of antibiotics on germ clearance rate and adverse reactions in respiratory infectious diseases.

Background: Atomizing inhalation of antibiotics is an innovative local drug delivery strategy.

Material and methods: PubMed, Medline, and Web of Science were searched systematically for appropriate clinical studies on atomizing inhalation of antibiotics for respiratory infectious diseases (patients diagnosed with respiratory infectious diseases; intervention: atomizing inhalation of antibiotics; comparison: oral or intravenous administration). Basic data recorded: sample size, follow-up time, germ clearance rate, adverse reactions and other outcome indicators. A meta-analysis was performed using RevMan 5.3 software.

Results: Six independent studies involving 245 patients with respiratory infectious diseases were included. There were 131 patients in the experimental group using atomizing inhalation of antibiotics and 114 patients in the control group utilizing oral or intravenous administration. Atomizing inhalation of antibiotics significantly increased the germ clearance rate (defined by no organism growth in culture and no visible organisms), and reduced number, frequency, and severity of adverse reactions compared with the controls.

Discussion: The advantages of atomizing inhalation of antibiotics may be attributed to the direct working of drugs on the infection site, increasing local drug concentrations, and thus killing germs more effectively. However, there are differences in the types and doses of antibiotics, atomizing units, and underlying diseases of patients across studies.

Conclusion: Atomizing inhalation of antibiotics exerts significantly better germ clearance effects while decreasing the incidence of adverse reactions than does oral or intravenous administration in the treatment of respiratory infectious diseases.

{"title":"Clinical effects of atomizing inhalation of antibiotics on germ clearance rate and adverse reactions in respiratory infectious diseases: A meta-analysis.","authors":"Chunyu Li, Jia Chen, Lujia Chen","doi":"10.5414/CP204722","DOIUrl":"10.5414/CP204722","url":null,"abstract":"<p><strong>Objective: </strong>To assess the effects of atomizing inhalation of antibiotics on germ clearance rate and adverse reactions in respiratory infectious diseases.</p><p><strong>Background: </strong>Atomizing inhalation of antibiotics is an innovative local drug delivery strategy.</p><p><strong>Material and methods: </strong>PubMed, Medline, and Web of Science were searched systematically for appropriate clinical studies on atomizing inhalation of antibiotics for respiratory infectious diseases (patients diagnosed with respiratory infectious diseases; intervention: atomizing inhalation of antibiotics; comparison: oral or intravenous administration). Basic data recorded: sample size, follow-up time, germ clearance rate, adverse reactions and other outcome indicators. A meta-analysis was performed using RevMan 5.3 software.</p><p><strong>Results: </strong>Six independent studies involving 245 patients with respiratory infectious diseases were included. There were 131 patients in the experimental group using atomizing inhalation of antibiotics and 114 patients in the control group utilizing oral or intravenous administration. Atomizing inhalation of antibiotics significantly increased the germ clearance rate (defined by no organism growth in culture and no visible organisms), and reduced number, frequency, and severity of adverse reactions compared with the controls.</p><p><strong>Discussion: </strong>The advantages of atomizing inhalation of antibiotics may be attributed to the direct working of drugs on the infection site, increasing local drug concentrations, and thus killing germs more effectively. However, there are differences in the types and doses of antibiotics, atomizing units, and underlying diseases of patients across studies.</p><p><strong>Conclusion: </strong>Atomizing inhalation of antibiotics exerts significantly better germ clearance effects while decreasing the incidence of adverse reactions than does oral or intravenous administration in the treatment of respiratory infectious diseases.</p>","PeriodicalId":13963,"journal":{"name":"International journal of clinical pharmacology and therapeutics","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143673830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immune-mediated hepatitis caused by toripalimab: A case report.
IF 0.9 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2025-03-21 DOI: 10.5414/CP204647
Taoyan Lin, Ping Zheng, Yilei Li, Jing Cai

Toripalimab, a humanized anti-PD-1 monoclonal antibody, is widely employed in the treatment of non-small cell lung cancer (NSCLC) and various other malignancies. However, there have been no reported cases linking prolonged administration of toripalimab to immune-mediated hepatitis (IMH). Typically, immune checkpoint inhibitor (ICI)-related IMH manifests within the first few weeks or months following the initiation of therapy. In this report, we presented a case of IMH in a patient with NSCLC following ~ 17 months of toripalimab treatment. IMH induced by toripalimab may occur at any time during treatment, underscoring the need for clinicians to remain vigilant in monitoring for adverse reactions. Throughout toripalimab treatment, careful attention must be paid to the symptoms, diagnosis, and pathological features of IMH. Glucocorticoids, such as methylprednisolone, can effectively reduce liver enzyme markers like aspartate aminotransferase and alanine aminotransferase in patients experiencing toripalimab-induced IMH.

{"title":"Immune-mediated hepatitis caused by toripalimab: A case report.","authors":"Taoyan Lin, Ping Zheng, Yilei Li, Jing Cai","doi":"10.5414/CP204647","DOIUrl":"10.5414/CP204647","url":null,"abstract":"<p><p>Toripalimab, a humanized anti-PD-1 monoclonal antibody, is widely employed in the treatment of non-small cell lung cancer (NSCLC) and various other malignancies. However, there have been no reported cases linking prolonged administration of toripalimab to immune-mediated hepatitis (IMH). Typically, immune checkpoint inhibitor (ICI)-related IMH manifests within the first few weeks or months following the initiation of therapy. In this report, we presented a case of IMH in a patient with NSCLC following ~ 17 months of toripalimab treatment. IMH induced by toripalimab may occur at any time during treatment, underscoring the need for clinicians to remain vigilant in monitoring for adverse reactions. Throughout toripalimab treatment, careful attention must be paid to the symptoms, diagnosis, and pathological features of IMH. Glucocorticoids, such as methylprednisolone, can effectively reduce liver enzyme markers like aspartate aminotransferase and alanine aminotransferase in patients experiencing toripalimab-induced IMH.</p>","PeriodicalId":13963,"journal":{"name":"International journal of clinical pharmacology and therapeutics","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143673832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
International journal of clinical pharmacology and therapeutics
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1